menu
    • menu

    Company profile for Glycomine

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat pho...
    Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    GlycomineUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    733 Industrial Rd, San Carlos, California 94070
    Telephone
    Telephone
    (650) 401-2016
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.glycomine.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/glycomine-inc-/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/glycominebio

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Natural Products Expo

    Natural Products Expo

    Not Confirmed

    envelop Contact Supplier

    Natural Products Expo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Glycomine Starts Global Phase 2b Trial of GLM101 for PMM2-CDG
    Glycomine Starts Global Phase 2b Trial of GLM101 for PMM2-CDG

    03 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-03/glycomine-initiates-dosing-in-a-global-randomized-placebo-controlled-phase-2b-study-of-glm101-for

    PHARMAWEB
    03 Sep 2025
    Share Share
    Glycomine secures $115M for GLM101 Phase 2b trial in PMM2-CDG
    Glycomine secures $115M for GLM101 Phase 2b trial in PMM2-CDG

    16 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250416688920/en/Glycomine-Announces-%24115-Million-Series-C-Financing-to-Advance-Lead-Drug-Candidate-GLM101-into-a-Phase-2b-Clinical-Trial-for-PMM2-CDG

    BUSINESSWIRE
    16 Apr 2025
    Share Share
    Glycomine Appoints Joshua Grass as Chairperson of Board of Directors
    Glycomine Appoints Joshua Grass as Chairperson of Board of Directors

    10 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241008340338/en

    BUSINESSWIRE
    10 Oct 2024
    Share Share
    Glycomine Gets FDA Fast Track For GLM101 In PMM2-CDG
    Glycomine Gets FDA Fast Track For GLM101 In PMM2-CDG

    18 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240918280418/en

    BUSINESSWIRE
    18 Sep 2024
    Share Share
    Glycomine Announces Encouraging Efficacy Data from Phase 2 Study in PMM2-CDG
    Glycomine Announces Encouraging Efficacy Data from Phase 2 Study in PMM2-CDG

    04 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240304707699/en

    BUSINESSWIRE
    04 Mar 2024
    Share Share
    Glycomine Announces First Pediatric Patient Dosed in Phase 2 Study of GLM101
    Glycomine Announces First Pediatric Patient Dosed in Phase 2 Study of GLM101

    11 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231211003939/en

    BUSINESSWIRE
    11 Dec 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search